Table 4.
Unmatched Group | Matched Group | |||||||
---|---|---|---|---|---|---|---|---|
TACE-Lenvatinib (n = 39) | TACE (n = 148) | P value | OR (95% CI) | TACE-Lenvatinib (n = 34) | TACE (n = 68) | P value | OR (95% CI) | |
CR | 3 (7.7%) | 3 (2.0%) | 0.202 | 4.03 (0.78–20.79) | 3 (8.8%) | 2 (2.9%) | 0.330 | 3.19 (0.51–20.10) |
PR | 22 (56.4%) | 51 (34.5%) | 0.012 | 2.46 (1.20–5.05) | 20 (58.8%) | 25 (36.8%) | 0.034 | 2.46 (1.06–5.71) |
SD | 6 (15.4%) | 46 (31.1%) | 0.052 | 0.40 (0.16–1.03) | 4 (11.8%) | 20 (29.4%) | 0.048 | 0.32 (0.10–1.03) |
PD | 8 (20.5%) | 48 (32.4%) | 0.148 | 0.54 (0.23–1.26) | 7 (20.6%) | 21 (30.9%) | 0.272 | 0.58 (0.22–1.54) |
ORR | 25 (64.1%) | 54 (36.5%) | 0.002 | 3.11 (1.49–6.48) | 23 (67.6%) | 27 (39.7%) | 0.008 | 3.18 (1.33–7.56) |
DCR | 31 (79.5%) | 100 (67.6%) | 0.148 | 1.86 (0.80–4.35) | 27 (79.4%) | 47 (69.1%) | 0.272 | 1.72 (0.65–4.58) |
Abbreviations: TACE, transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable response; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; OR, odds ratio; CI, confidence interval.